LM22A-4

• CAT Number: I003394
• CAS Number: 37988-18-4
• Molecular Formula: C15H21N3O6
• Molecular Weight: 339.35
• Purity: ≥95%
• Synonyms: (1Z,3Z,5Z)-N/’1,N/’3,N/’5-tris(2-hydroxyethyl)benzene-1,3,5-tris(carboxylimidic acid)
• Target: Protein Tyrosine Kinase/RTK
• Solubility: DMSO: ≥ 29 mg/mL
• Storage: Store at +4C
• IUPAC Name: 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide
• InChI: InChI=1S/C15H21N3O6/c19-4-1-16-13(22)10-7-11(14(23)17-2-5-20)9-12(8-10)15(24)18-3-6-21/h7-9,19-21H,1-6H2,(H,16,22)(H,17,23)(H,18,24)
• InChIKey: RGWJKANXFYJKHN-UHFFFAOYSA-N
• SMILES: C1=C(C=C(C=C1C(=O)NCCO)C(=O)NCCO)C(=O)NCCO

LM22A-4 (Cat No.: I003394) is a small-molecule agonist of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) receptors, specifically TrkB and TrkC. It mimics neurotrophins, promoting neuronal survival, synaptic plasticity, and axonal growth, making it a potential therapeutic candidate for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and spinal cord injuries. Unlike BDNF, LM22A-4 is blood-brain barrier permeable, allowing easier central nervous system penetration. Studies suggest it enhances cognitive function and neuroprotection, offering promise for treating neurological disorders and brain injuries.

Reference

[1]. Yu G, et al. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. eCollection 2015.
[2]. Kajiya M, et al. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade. Int Immunopharmacol. 2014 Apr;19(2):245-52.